Creative Medical stock increased 18% due to FDA's orphan drug designation for CELZ-101 as a Type 1 diabetes treatment.
Creative Medical stock rallied 18% on FDA's orphan drug designation for CELZ-101 (ImmCelz), a therapy candidate for brittle Type 1 diabetes treatment. The FDA granted the designation for preventing allograft rejection in patients undergoing pancreatic islet cell transplantation. CELZ-101 focuses on using a patient's regulatory T cells to address autoimmune and alloimmune reactions.
March 06, 2024
3 Articles